Blueprint Medicines 관리
관리 기준 확인 3/4
Blueprint Medicines CEO는 Kate Haviland, Apr2022 에 임명되었습니다 의 임기는 2.58 년입니다. 총 연간 보상은 $ 6.43M, 12.2% 로 구성됩니다. 12.2% 급여 및 87.8% 보너스(회사 주식 및 옵션 포함). 는 $ 5.98M 가치에 해당하는 회사 주식의 0.094% 직접 소유합니다. 5.98M. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 9.5 년입니다.
주요 정보
Kate Haviland
최고 경영자
US$6.4m
총 보상
| CEO 급여 비율 | 12.2% |
| CEO 임기 | 2.6yrs |
| CEO 소유권 | 0.09% |
| 경영진 평균 재임 기간 | 4.2yrs |
| 이사회 평균 재임 기간 | 9.5yrs |
최근 관리 업데이트
Recent updates
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In
Sep 27Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?
Aug 16
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S
Jul 23Blueprint Medicines: Overdue For A Breather
Jul 16Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 05Blueprint Medicines: Rampant Growth Mostly Priced In
May 04Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$128m |
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
| Sep 30 2018 | n/a | n/a | -US$205m |
| Jun 30 2018 | n/a | n/a | -US$170m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$1m | US$353k | -US$148m |
보상 대 시장: Kate 의 총 보상 ($USD 6.43M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 7.84M ).
보상과 수익: 회사가 수익성이 없는 동안 Kate 의 보상이 증가했습니다.
CEO
Kate Haviland (48 yo)
2.6yrs
테뉴어
US$6,432,012
보상
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 2.6yrs | US$6.43m | 0.094% $ 6.0m | |
| Co-Founder & Director | no data | US$397.33k | 0.11% $ 7.2m | |
| Chief Financial Officer | 8.8yrs | US$2.19m | 0.056% $ 3.6m | |
| Chief Operating Officer | 2.6yrs | US$2.81m | 0.043% $ 2.7m | |
| Chief Scientific Officer | 3.5yrs | US$2.30m | 0.078% $ 4.9m | |
| President of Research & Development | 4.2yrs | US$2.80m | 0.050% $ 3.2m | |
| Senior VP | 1.8yrs | 데이터 없음 | 0.023% $ 1.5m | |
| Senior Director & Head of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | 8.2yrs | US$2.34m | 0.046% $ 2.9m | |
| Chief People Officer | 4.8yrs | 데이터 없음 | 0.019% $ 1.2m | |
| Senior Vice President of Corporate Affairs | no data | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | 4.5yrs | 데이터 없음 | 0.046% $ 2.9m |
4.2yrs
평균 재임 기간
54yo
평균 연령
경험이 풍부한 관리: BPMC 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 2.6yrs | US$6.43m | 0.094% $ 6.0m | |
| Co-Founder & Director | 13.6yrs | US$397.33k | 0.11% $ 7.2m | |
| Chair of Scientific Advisory Board | 12.5yrs | US$333.38k | 데이터 없음 | |
| Lead Independent Director | 8.6yrs | US$452.33k | 0.017% $ 1.1m | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board & Independent Director | 13.6yrs | US$417.33k | 0.088% $ 5.6m | |
| Independent Director | 8.8yrs | US$419.33k | 0.017% $ 1.1m | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.9yrs | US$422.33k | 0.014% $ 859.0k | |
| Chairman | 10.3yrs | US$526.08k | 0.24% $ 15.5m |
9.5yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 이사회: BPMC 의 이사회는 경험(평균 재직 기간 9.5 년)으로 간주됩니다.